Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
JERSEY CITY, N.J., March 29, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central on Wednesday, April 5, 2017 at 1:40 p.m. ET.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
